Harrow Health, Inc.

NasdaqGM HROW

Harrow Health, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -8.57 M

Harrow Health, Inc. Operating Income is USD -8.57 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -1,106.10% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Harrow Health, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 852.00 K, a 190.25% change year over year.
Harrow Health, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -944.00 K, a -115.75% change year over year.
Harrow Health, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 6.00 M, a 553.14% change year over year.
Harrow Health, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -1.32 M, a 83.22% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGM: HROW

Harrow Health, Inc.

CEO	Mr. Mark L. Baum J.D.
IPO Date	Sept. 28, 2007
Location	United States
Headquarters	102 Woodmont Boulevard
Employees	315
Sector	Consumer Discretionary
Industries Eyewear Biotechnology Clinical Trials Cosmetics Dental Care Drugstores & Retail Pharmacies Personal Care Pharmaceuticals

Description

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Key trends

Past 5 years